Medical Developments International Limited MVP
ASX · Australia · Health Technology
AUD 0.4250-0.01 (-2.30%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Strong Penthrox demand and improved cash flow offset respiratory weakness and FX headwinds.
As Australian shares edge up with a 0.4% advance, the market is showing resilience amid global uncertainties and potential interest rate decisions. In this climate, investors often turn their attention to penny stocks—companies that may be smaller or newer but can offer intriguing opportunities when backed by solid financials. Despite their vintage name, these stocks continue to capture interest for their potential to uncover hidden value and growth prospects in the ever-evolving market...
Medical Developments International Ltd (MDDVF) reports an 8% revenue increase, driven by a robust 18% growth in pain management, while facing a 10% decline in the respiratory segment.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.